Skip to content
Screener

uniQure QURE Financing Cash Flow

Financing Cash Flow at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$241K-98.1%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$711K+1,467%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-32.0%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$19.93M+86,570%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$93.82M+5,117%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%

Other financials

Income statement

See full
Revenue$5.8M+11.0%
Gross profit$5.5M+19.2%
Operating income-$52.2M-19.0%
Net income-$81.1M-115%
EPS (diluted)-$1.22-76.8%

Balance sheet

See full
Cash & equivalents$413.0M+62.8%
Total debt$62.8M-5.8%
Total equity$324.1M+8,195%
Total assets$985.1M+68.4%

Cash flow

See full
Operating cash flow-$28.6M+28.4%
CapEx$472.0K+81.5%
Free cash flow-$29.0M+27.7%

Valuation

See full
Market cap$3.15B+325%
Enterprise value$2.8B+406%
P/S168.5×+117×

Profitability

See full
Gross margin92.5%+4.6pp
Operating margin-1,071.5%-90.6pp
Net margin-1,350.7%-35.3pp
FCF margin-864.7%-194pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.2×
Current ratio10×0.0×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: uniQure’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 7:17 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087815
Line itemSix months ended June 30, 2026Six months ended June 30, 2025
Cash flows from financing activities
Proceeds from follow-on public offering of ordinary shares, net of issuance costs242,68180,511
Proceeds from issuance of ordinary shares related to employee stock options and purchase plans6,985203
Net cash generated from financing activities249,66680,714
Currency effect on cash, cash equivalents and restricted cash(1,906)5,052
Net increase in cash, cash equivalents and restricted cash332,76094,943
Cash, cash equivalents and restricted cash at the beginning of period81,801160,329
Cash, cash equivalents and restricted cash at the end of period$414,561$255,272

Item 1.Financial Statements

FAQ

What is uniQure's financing cash flow?
uniQure (QURE) reported financing cash flow of $249.12M in Q2 2026.
How has uniQure's financing cash flow changed year-over-year?
uniQure's financing cash flow increased by 566072.7% year-over-year, from $44K to $249.12M.
What is the long-term trend for uniQure's financing cash flow?
Over 3 years (2021 to 2025), uniQure's financing cash flow has grown at a 63.5% compound annual growth rate (CAGR), from $95.02M to $415.4M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about uniQure's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude